Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib

详细信息    查看全文

• 作者：Carlos Ferná ; ndez de Larrea^a ; ¹ ; Beatriz Martí ; n-Antonio^a ; ¹ ; Maria Teresa Cibeira^a ; Alfons Navarro^b ; Natalia Tovar^a ; Tania Dí ; az^b ; Laura Rosi&ntilde ; ol^a ; Mariano Monzó ; ^b ; Alvaro Urbano-Ispizua^a ; Joan Bladé ; ^a ; ^{jblade@clinic.ub.es}
• 关键词：Bortezomib ; DNA ; Methylation ; Myeloma ; Prognosis ; NFKB1
• 刊名：Leukemia Research
• 出版年：2013
• 出版时间：June, 2013
• 年：2013
• 卷：37
• 期：6
• 页码：641-646
• 全文大小：430 K

文摘

We studied seventy-five patients with relapsed MM treated with bortezomib-based regimens. DNA was isolated from bone marrow samples at the time of relapse. Global methylation was determined by ELISA, and CpG island DNA methylation profile of 30 genes by a DNA methylation PCR system. Patients with more than 3.95 % of total DNA methylated achieved better overall survival (OS) (p = 0.004). A relatively low methylation percentage (<1.07 % ) of NFKB1 was also associated with longer OS after bortezomib treatment (p = 0.015). The combination of highly methylated global genome with low NFKB1 methylation status defined a specific subset of patients with better prognosis.